BR112022004712A2 - Compostos e métodos de imunoterapia - Google Patents

Compostos e métodos de imunoterapia

Info

Publication number
BR112022004712A2
BR112022004712A2 BR112022004712A BR112022004712A BR112022004712A2 BR 112022004712 A2 BR112022004712 A2 BR 112022004712A2 BR 112022004712 A BR112022004712 A BR 112022004712A BR 112022004712 A BR112022004712 A BR 112022004712A BR 112022004712 A2 BR112022004712 A2 BR 112022004712A2
Authority
BR
Brazil
Prior art keywords
domain
methods
cell
immunotherapy
her2
Prior art date
Application number
BR112022004712A
Other languages
English (en)
Inventor
A Vallera Daniel
S Miller Jeffrey
Martin Felices
Martin Schroeder
Original Assignee
Gt Biopharma Inc
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gt Biopharma Inc, Univ Minnesota filed Critical Gt Biopharma Inc
Publication of BR112022004712A2 publication Critical patent/BR112022004712A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

compostos e métodos de imunoterapia. a presente invenção refere-se a um composto de imunoterapia que inclui um domínio de envolvimento de células nk, um domínio de ativação nk e um domínio de direcionamento. o domínio de direcionamento se liga seletivamente ao her2, her3 ou ao complexo heterodímero her2/her3 e está ligado de maneira funcional ao domínio de ativação de nk e ao domínio de envolvimento das células nk. o composto pode ser administrado a um indivíduo para induzir a morte de uma célula cancerígena mediada por nk, para estimular a expansão das células nk no indivíduo e/ou para tratar o câncer.
BR112022004712A 2019-09-16 2020-09-15 Compostos e métodos de imunoterapia BR112022004712A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962901198P 2019-09-16 2019-09-16
PCT/US2020/050851 WO2021055342A1 (en) 2019-09-16 2020-09-15 Immunotherapy compounds and methods

Publications (1)

Publication Number Publication Date
BR112022004712A2 true BR112022004712A2 (pt) 2022-06-14

Family

ID=74883667

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004712A BR112022004712A2 (pt) 2019-09-16 2020-09-15 Compostos e métodos de imunoterapia

Country Status (10)

Country Link
US (1) US20220324972A1 (pt)
EP (1) EP4031565A4 (pt)
JP (1) JP2022548145A (pt)
KR (1) KR20220087441A (pt)
CN (1) CN115023435A (pt)
AU (1) AU2020350524A1 (pt)
BR (1) BR112022004712A2 (pt)
CA (1) CA3154158A1 (pt)
IL (1) IL291343A (pt)
WO (1) WO2021055342A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024534467A (ja) * 2021-09-16 2024-09-20 ジーティー バイオファーマ インコーポレイテッド Ｐｄ－ｌ１標的指向融合タンパク質及びそれらの使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2878587A1 (en) * 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
CA2924398A1 (en) * 2013-11-05 2015-05-14 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
PL3160498T3 (pl) * 2014-06-30 2022-02-21 Altor Bioscience Corporation Cząsteczki na bazie IL-15 i sposoby ich zastosowania
EP3359168A4 (en) * 2015-10-06 2019-08-07 Regents of the University of Minnesota THERAPEUTIC COMPOUNDS AND METHODS
CN109153728A (zh) * 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF

Also Published As

Publication number Publication date
AU2020350524A1 (en) 2022-04-21
EP4031565A4 (en) 2023-10-25
US20220324972A1 (en) 2022-10-13
JP2022548145A (ja) 2022-11-16
CA3154158A1 (en) 2021-03-25
KR20220087441A (ko) 2022-06-24
EP4031565A1 (en) 2022-07-27
CN115023435A (zh) 2022-09-06
WO2021055342A1 (en) 2021-03-25
IL291343A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
CL2022002448A1 (es) Constructos de anticuerpo para flt3 y cd3 (divisional sol.: 201800269)
BR112021011431A2 (pt) Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CL2019000277A1 (es) Tratamiento conjunto contra el cáncer.
BR112019002035A2 (pt) tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
MA40074A (fr) Composés liant ras multivalents
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
EA202091540A1 (ru) Антитела к lilrb2
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112019000071A2 (pt) conjugados adjuvantes de anticorpo
CR20180048A (es) Anticuerpos pd-l1 ("ligando de muerte programada 1")
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
PE20160753A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
ECSP109985A (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
BR112018013653A2 (pt) anticorpos anti-pd-1
BR112012016820A2 (pt) Metodos para tratamento de cancer de seio
CL2019000585A1 (es) Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos.
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
AR115288A1 (es) Anticuerpos humanizados contra el psma
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20